Venkat Jasti, the chairman and CEO of Suven Life Sciences, spoke to CNBC-TV18 about the company's business plans and growth prospects.
“We have announced the demerger of Suven Life Sciences into CRAMS. We have started a US company Suven Pharma. It has more than 120 active products under abbreviated new drug applications (ANDA) development,” Jasti said on Tuesday.
In terms of Rising Pharma’s ANDAs, he added, “121 are commercialised and other 89 are under development.”
Speaking about the company’s plan with the contract research and manufacturing services (CRAMS) business, Jasti said, “As of now, we are not getting any investor.”
The CRAMS business is the bread earner for the company and has grown strongly over the last three years, according to a note by Kotak Securities.
On SUVN-502, Alzheimer drug development, Jasti said, “We have enrolled 550 patients. We are hoping to present our data in mid-July in the Alzheimer’s conference in Los Angeles.”